Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients (0653A-172)(COMPLETED)

Phase 4 Completed 173 enrolled Organon and Co

Non-randomizedSingle-groupOpen-labelTreatment

The purpose of this study is to determine the safety and tolerability of ezetimibe/simvastatin in patients newly diagnosed with dyslipidemia.

Evaluation	Drug	Modality	Dose	Route
Subject	Ezetimibe	Unknown	10 mg	Oral
Subject	Simvastatin	Small molecule	20 mg	Oral